TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, announced today that it has received written authorization from the U.S. Food and Drug Administration (FDA) that it may proceed with its First-in-Human (FIH) Phase 0 clinical trial. The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in up to 12 cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode believes that TTX-MC138 could be used as a treatment for many of these cancers.
Pepe Coin Bucks Trend with 12% Surge, Outpacing Dogecoin, Shiba Inu — Can PEPE Reach $1?
Pepe Coin (CRYPTO: PEPE), a budding meme-based cryptocurrency, has taken the market by surprise with a 12% surge in value over the past 24 hours, outpacing gains made by other meme coins such as Dogecoin (CRYPTO: DOGE) and Sh